WhiteSands Treatment Center Publishes New Resource on Safe Buspirone Tapering

ORLANDO, FL - March 02, 2026 - PRESSADVANTAGE - WhiteSands Treatment Center has published a new educational resource on ...
The National Law Review

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market ...